Dianthus Therapeutics GAAP EPS of -$0.97

* Dianthus Therapeutics press release [https://seekingalpha.com/pr/20295274-dianthus-therapeutics-highlights-recent-business-achievements-and-reports-q3-financial] (DNTH [https://seekingalpha.com/symbol/DNTH]): Q3 GAAP EPS of -$0.97.
* Cash Position – An estimated $525 million of adjusted cash, cash equivalents and investments as of September 30, 2025 is projected to provide runway into 2028. This $525 million estimate includes cash, cash equivalents and investments as of September 30, 2025 of approximately $555.5 million, less $30 million of upfront and near-term milestone payments payable to Leads Biolabs.
*

MORE ON DIANTHUS THERAPEUTICS

* Dianthus Therapeutics, Inc. (DNTH) Phase 2 MaGic Data Investor Webcast Transcript [https://seekingalpha.com/article/4820799-dianthus-therapeutics-inc-dnth-phase-2-magic-data-investor-webcast-transcript]
* Dianthus Therapeutics, Inc. (DNTH) Phase 2 MaGic Data - Slideshow [https://seekingalpha.com/article/4820747-dianthus-therapeutics-inc-dnth-special-call-slideshow]
* Dianthus to license autoimmune disease candidate in a deal worth up to $1B [https://seekingalpha.com/news/4504876-dianthus-license-autoimmune-disease-candidate]
* Dianthus Therapeutics prices upsized $251M securities offering [https://seekingalpha.com/news/4493589-dianthus-therapeutics-prices-upsized-251m-securities-offering]
* Seeking Alpha’s Quant Rating on Dianthus Therapeutics [https://seekingalpha.com/symbol/DNTH/ratings/quant-ratings]